Seaport’s IPO Arrives With More Book Shape Than Most Biotechs

BOSTON, April 29, 2026 — Seaport Therapeutics is not just another pre-revenue biotech trying to sneak onto a softer window. The Boston neuropsychiatry issuer has put more shape around its IPO than most companies at this stage: the latest prospectus lays out 11.8 million shares at $16 to $18, a Goldman Sachs-led syndicate, up to $50 million of indicated interest from entities affiliated with General Atlantic, and room for as much as $20 million from existing holders in a concurrent private placement on the same terms.

That matters because Seaport is still selling a clinical story, not a revenue line. At the midpoint, the deal would raise about $200.6 million gross before the greenshoe, with net proceeds of roughly $183.5 million, and the company says that cash, added to its $233.7 million cash balance at December 31, 2025, should fund three visible shots on goal: GlyphAllo in major depressive disorder, GlyphAgo in generalized anxiety disorder, and Glyph2BLSD in other neuropsychiatric work. The same filing says GlyphAllo Phase 2b topline data are expected in the first half of 2027, while GlyphAgo’s next efficacy readouts are pushed into 2028, so public buyers are underwriting time as much as science.

The demand signals are the real color here. General Atlantic is not a random name in the book-building section; it also led Seaport’s oversubscribed $225 million Series B in October 2024, a round that brought total private funding to $325 million and also included T. Rowe Price, Foresite, Invus, Goldman Sachs Alternatives and CPP Investments. In the IPO filing, Seaport also discloses that PureTech, its original backer, would still own a large stake after the offering, which helps explain why this deal looks more like a sponsored crossover financing coming into the public market than a thinly supported biotech launch.

That does not make it safe. Seaport posted a $74.9 million net loss in 2025, has no product revenue, and is asking investors to back a platform thesis in one of biotech’s hardest categories. But a five-bank roster of Goldman, J.P. Morgan, Leerink, Citi and Stifel, a fresh 8-A filing for Nasdaq trading under SPTX, and an April data update showing positive Phase 1 proof-of-concept results for GlyphAgo give the setup more momentum than the average neuroscience IPO. The question now is not whether Seaport can tell the story. It is whether that pre-shaped order book is strong enough to carry another risk-heavy biotech through pricing.